Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 2
Submit an article Journal homepage
3,206
Views
18
CrossRef citations to date
0
Altmetric
Original Articles

Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)

Morton Colemana Clinical Research Alliance/Weill Cornell Medicine, New York, NY, USAView further author information
,
David Beladab 4th Department of Internal Medicine – Haematology, Charles University, Hospital and Faculty of Medicine, Hradec Králové, Czech RepublicView further author information
,
René-Olivier Casasnovasc University Hospital F. Mitterrand and Inserm UMR 1231, Dijon, FranceView further author information
,
Rémy Gressind Department of Oncohaematology, University Hospital Grenoble-Alpes, Grenoble, France;e Institute for Advanced Biosciences, Inserm U 823, Grenoble, FranceView further author information
,
Hui-Peng Leef Flinders Medical Centre, Bedford Park, SA, AustraliaView further author information
,
Amitkumar Mehtag UAB School of Medicine, Birmingham, AL, USAORCID Iconhttps://orcid.org/0000-0003-0537-4207View further author information
ORCID Icon,
Javier Munozh Banner MD Anderson Cancer Center, Gilbert, AZ, USAView further author information
,
Gregor Verhoefi Department of Hematology, University Hospitals Leuven, Leuven, BelgiumView further author information
,
Claudia Corradoj Incyte Corporation, Wilmington, DE, USAView further author information
,
Douglas J. DeMarinij Incyte Corporation, Wilmington, DE, USAView further author information
,
Wanying Zhaoj Incyte Corporation, Wilmington, DE, USAView further author information
,
Jia Lij Incyte Corporation, Wilmington, DE, USAView further author information
&
Keith Fayk Department of Haematology, St Vincent’s Hospital, Darlinghurst, NSW, AustraliaCorrespondence[email protected]
View further author information
 show all
Pages 368-376 | Received 14 May 2020, Accepted 23 Sep 2020, Published online: 03 Nov 2020

References

  • Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74–87.
  • Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–511.
  • NCCN Guidelines® B-Cell Lymphomas Version 1.2020. U.S. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2020. https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf
  • Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program. 2016;2016(1):366–378.
  • Jurczak W, Długosz-Danecka M, Rivas Navarro F. The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions. Future Oncol. 2019;15(3):305–317.
  • IMBRUVICA® (ibrutinib) capsules, for oral use, tablets, for oral use, U.S. Sunnyvale (CA): Pharmacyclics LLC; 2019.
  • Skrabek P, Assouline S, Christofides A, et al. Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma. Curr Oncol. 2019;26(4):253–265.
  • Van Den Neste E, Schmitz N, Mounier N, et al. Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study. Bone Marrow Transplant. 2016;51(1):51–57.
  • Allen JC, Talab F, Slupsky JR. Targeting B-cell receptor signaling in leukemia and lymphoma: how and why? Int J Hematol Oncol. 2016;5(1):37–53.
  • Miao Y, Medeiros LJ, Xu-Monette ZY, et al. Dysregulation of cell survival in diffuse large B cell lymphoma: mechanisms and therapeutic targets. Front Oncol. 2019;9:107.
  • Valla K, Flowers CR, Koff JL. Targeting the B cell receptor pathway in non-Hodgkin lymphoma. Expert Opin Investig Drugs. 2018;27(6):513–522.
  • Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7–24.
  • Puri KD, Gold MR. Selective inhibitors of phosphoinositide 3-kinase delta: modulators of B-cell function with potential for treating autoimmune inflammatory diseases and B-cell malignancies. Front Immunol. 2012;3:256.
  • ZYDELIG® (idelalisib) tablets, for oral use. U.S. Foster City (CA): Gilead Sciences, Inc.; 2018.
  • COPIKTRA (duvelisib), capsules for oral use. U.S. Needham (MA): Verastem Inc.; 2019.
  • ALIQOPA™ (copanlisib) for injection, for intravenous use. U.S. Whippany (NJ): Bayer HealthCare Pharmaceuticals Inc.; 2019.
  • Shin N, Koblish H, Covington M, et al. Abstract 2671: INCB050465, a novel PI3Kδ inhibitor, synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL. Cancer Res. 2015;75(15 Supplement):2671–2671.
  • Forero-Torres A, Wertheim MS, Phillips TJ, et al. Abstract CT056: Preliminary safety, efficacy, and pharmacodynamics of a highly selective PI3Kδ inhibitor, INCB050465, in patients with previously treated B-cell malignancies. Cancer Res. 2016;76(14 Supplement):CT056–CT056.
  • Forero-Torres A, Ramchandren R, Yacoub A, et al. Parsaclisib, a potent and highly selective PI3Kδ inhibitor, in patients with relapsed or refractory B-cell malignancies. Blood. 2019;133(16):1742–1752.
  • Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–3068.
  • Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800–1808.
  • Lenz G, Hawkes E, Verhoef G, et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia. 2020;34(8):2184–2197.
  • Young RM, Shaffer AL, 3rd, Phelan JD, et al. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol. 2015;52(2):77–85.
  • Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton's tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.